S
Samantha Cooper
Researcher at Bio-Rad Laboratories
Publications - 12
Citations - 344
Samantha Cooper is an academic researcher from Bio-Rad Laboratories. The author has contributed to research in topics: Digital polymerase chain reaction & KRAS. The author has an hindex of 5, co-authored 12 publications receiving 270 citations.
Papers
More filters
Journal ArticleDOI
Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing.
Yuichiro Miyaoka,Jennifer R. Berman,Samantha Cooper,Steven J. Mayerl,Amanda H. Chan,Bin Zhang,George Karlin-Neumann,Bruce R. Conklin +7 more
TL;DR: A novel, rapid, digital PCR–based assay that can simultaneously detect one HDR or NHEJ event out of 1,000 copies of the genome will enable mechanistic studies of genome-editing and help improve genome-EDiting technology.
Journal ArticleDOI
A Rapid Molecular Approach for Chromosomal Phasing
John F. Regan,Nolan Kamitaki,Tina C. Legler,Samantha Cooper,Niels Klitgord,George Karlin-Neumann,Catherine Wong,Shawn Hodges,Ryan T. Koehler,Svilen Tzonev,Steven A. McCarroll +10 more
TL;DR: Drop-Phase is a molecular method for quickly ascertaining the phase of pairs of DNA sequence variants (separated by 1-200 kb) without cloning or manual single-molecule dilution, and effective at long genomic distances (200 kb).
Journal ArticleDOI
Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
Broderick Corless,Gregory Chang,Samantha Cooper,Mahrukh M. Syeda,Yongzhao Shao,Iman Osman,George Karlin-Neumann,David Polsky +7 more
TL;DR: Development of novel probe-based droplet digital PCR assays that specifically detect and quantify TERTmutant DNA in tumors and plasma of cancer patients are described and their application using human tumor and plasma samples from melanoma patients is demonstrated.
Journal ArticleDOI
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma
Hestia Mellert,Trudi Foreman,Leisa Jackson,Dianna Maar,Scott Thurston,Kristina Koch,Amanda Weaver,Samantha Cooper,Nicholas F. Dupuis,Ubaradka G. Sathyanarayana,Jakkie Greer,Westen Hahn,Dawne N. Shelton,Paula Stonemetz,Gary Pestano +14 more
TL;DR: This study validates a blood-based genome-testing service that provides accurate results within 72 hours for targetable variants in advanced non-small cell lung carcinoma-epidermal growth factor receptor gene (EGFR) variant L858R, exon 19 deletion (ΔE746-A750), and T790M.
Patent
Digital assays for mutation detection
TL;DR: In this article, methods, compositions, and kits for detecting allelic variants using a single probe or a single primer set are presented, as well as methods and compositions for determining a polymerization error rate.